药明生物(02269.HK)与拜耳就一家位于德国的生物制剂工厂达成收购协议
原创:WuXi Biologic
这将成为药明生物首个欧洲生物制剂厂,有力补充公司全球商业化生产能力;
药明生物将作为拜耳公司产品科跃奇®的辅助生产服务商。

全球领先的开放式生物制药技术平台公司药明生物(WuXi Biologics, 2269.HK)和拜耳2020年1月16日共同宣布达成一项协议,药明生物将接管拜耳在德国勒沃库森一家生物制剂工厂的运营工作、购买相关设备,以及该厂房所附的一项长期租赁合同。
根据商议中的生产合作协议,该工厂将由药明生物负责运营,并作为拜耳公司产品科跃奇®(重组抗血友病因子)的辅助生产服务商。在满足惯例成交条件的基础上,此项交易计划在未来几个月内完成。相关财务细节未披露。
“我们很高兴与拜耳签署收购协议,以进一步快速提升公司高质量制剂生产能力。”药明生物首席执行官陈智胜博士表示,“药明生物近年来在欧盟、美国和中国三大市场的业务保持高速增长,此项收购进一步彰显了公司持续践行‘药明生物提供全球双厂生产战略。药明生物将不断扩充生物制药产能,通过公司健全强大的全球供应链网络为客户提供高质量生物药,造福广大病患。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.